# Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

> **NCT03720470** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 838 (actual)

## Conditions studied

- Dermatitis
- Dermatitis, Atopic
- Eczema
- Skin Diseases
- Skin Diseases, Genetic
- Genetic Diseases, Inborn
- Skin Diseases, Eczematous
- Hypersensitivity
- Hypersensitivity, Immediate
- Immune System Diseases

## Interventions

- **DRUG:** PF-04965842 100 mg
- **DRUG:** PF-04965842 200 mg
- **DRUG:** Dupilumab
- **DRUG:** Oral Placebo
- **DRUG:** Injectable Placebo

## Key facts

- **NCT ID:** NCT03720470
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-29
- **Primary completion:** 2019-12-27
- **Final completion:** 2020-03-06
- **Target enrollment:** 838 (ACTUAL)
- **Last updated:** 2021-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03720470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03720470, "Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03720470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*